Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dafna Gladman

Showing results (51-60 of 86) with videos related to

Pageof 9
Sort By:
Arthritis and Rheumatism|April 1, 2009
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled studyArthur Kavanaugh, Iain McInnes, Philip Mease, et al.
The Journal of Rheumatology|December 4, 2009
The use of micronutrient supplements is not associated with better quality of life and disease activity in Canadian patients with systemic lupus erythematosusElaheh Aghdassi, Stacey Morrison, Carolina Landolt-Marticorena, et al.
Annals of the Rheumatic Diseases|April 22, 2014
Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)Arthur Kavanaugh, Iain B McInnes, Philip Mease, et al.
The Journal of Rheumatology|September 3, 2019
The Relationship Between Physical Examination and Ultrasonography of Large Entheses of the Achilles Tendon and Patellar Tendon OriginSibel Zehra Aydin, Sibel Bakirci, Esen Kasapoglu, et al.
Journal of the American Academy of Dermatology|March 4, 2008
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screeningAlexa B Kimball, Dafna Gladman, Joel M Gelfand, et al.
Rheumatology (Oxford, England)|September 7, 2014
Anti-nucleosome antibodies outperform traditional biomarkers as longitudinal indicators of disease activity in systemic lupus erythematosusTimothy Li, Stephenie D Prokopec, Stacey Morrison, et al.
Arthritis and Rheumatism|December 4, 2010
Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trialPhilip Mease, Mark C Genovese, Geoffrey Gladstein, et al.
Seminars in Arthritis and Rheumatism|May 19, 2012
Neuropsychiatric lupus: the prevalence and autoantibody associations depend on the definition: results from the 1000 faces of lupus cohortAlan M Borowoy, Janet E Pope, Earl Silverman, et al.
Annals of the Rheumatic Diseases|September 15, 2012
Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumabCarrie L Wagner, Sudha Visvanathan, Michael Elashoff, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 24, 2012
Evaluation of clinical outcomes and renal vascular pathology among patients with lupusClaire Barber, Andrew Herzenberg, Ellie Aghdassi, et al.
Pageof 9

Showing results (51-60 of 86) with videos related to

Sort By:
Pageof 9
Arthritis and Rheumatism|April 1, 2009
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled studyArthur Kavanaugh, Iain McInnes, Philip Mease, et al.
The Journal of Rheumatology|December 4, 2009
The use of micronutrient supplements is not associated with better quality of life and disease activity in Canadian patients with systemic lupus erythematosusElaheh Aghdassi, Stacey Morrison, Carolina Landolt-Marticorena, et al.
Annals of the Rheumatic Diseases|April 22, 2014
Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)Arthur Kavanaugh, Iain B McInnes, Philip Mease, et al.
The Journal of Rheumatology|September 3, 2019
The Relationship Between Physical Examination and Ultrasonography of Large Entheses of the Achilles Tendon and Patellar Tendon OriginSibel Zehra Aydin, Sibel Bakirci, Esen Kasapoglu, et al.
Journal of the American Academy of Dermatology|March 4, 2008
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screeningAlexa B Kimball, Dafna Gladman, Joel M Gelfand, et al.
Rheumatology (Oxford, England)|September 7, 2014
Anti-nucleosome antibodies outperform traditional biomarkers as longitudinal indicators of disease activity in systemic lupus erythematosusTimothy Li, Stephenie D Prokopec, Stacey Morrison, et al.
Arthritis and Rheumatism|December 4, 2010
Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trialPhilip Mease, Mark C Genovese, Geoffrey Gladstein, et al.
Seminars in Arthritis and Rheumatism|May 19, 2012
Neuropsychiatric lupus: the prevalence and autoantibody associations depend on the definition: results from the 1000 faces of lupus cohortAlan M Borowoy, Janet E Pope, Earl Silverman, et al.
Annals of the Rheumatic Diseases|September 15, 2012
Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumabCarrie L Wagner, Sudha Visvanathan, Michael Elashoff, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 24, 2012
Evaluation of clinical outcomes and renal vascular pathology among patients with lupusClaire Barber, Andrew Herzenberg, Ellie Aghdassi, et al.
Pageof 9